VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 74 filers reported holding VERVE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $68,959,525 | -28.6% | 5,200,567 | +1.0% | 0.53% | -17.4% |
Q2 2023 | $96,578,455 | +49.4% | 5,150,851 | +14.9% | 0.64% | +43.9% |
Q1 2023 | $64,631,752 | -23.5% | 4,482,091 | +2.7% | 0.44% | -39.3% |
Q4 2022 | $84,478,811 | -27.5% | 4,365,830 | +28.6% | 0.73% | -10.0% |
Q3 2022 | $116,579,000 | +278.0% | 3,393,859 | +66.8% | 0.81% | +346.7% |
Q2 2022 | $30,837,000 | -19.9% | 2,034,124 | +20.6% | 0.18% | +13.0% |
Q1 2022 | $38,496,000 | -25.4% | 1,686,945 | +20.5% | 0.16% | +3.2% |
Q4 2021 | $51,601,000 | -13.4% | 1,399,545 | +10.4% | 0.16% | +9.1% |
Q3 2021 | $59,582,000 | +80.3% | 1,267,705 | +131.2% | 0.14% | +134.4% |
Q2 2021 | $33,040,000 | – | 548,389 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARCH Venture Management, LLC | 2,508,809 | $57,251,000 | 8.18% |
Alphabet Inc. | 10,974,011 | $250,427,000 | 8.12% |
M28 Capital Management LP | 178,500 | $4,073,000 | 3.74% |
Casdin Capital, LLC | 3,138,167 | $71,613,000 | 3.21% |
Ally Bridge Group (NY) LLC | 105,360 | $2,404,000 | 1.78% |
Redmile Group, LLC | 1,835,328 | $41,882,000 | 1.31% |
Cormorant Asset Management, LP | 700,710 | $15,990,000 | 1.23% |
Novo Holdings A/S | 750,000 | $17,115,000 | 0.90% |
Artal Group S.A. | 400,000 | $9,128,000 | 0.38% |
PFM Health Sciences, LP | 369,765 | $8,438,000 | 0.32% |